...
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer
【24h】

Comparison of EUS-guided fine needle aspiration and integrated PET-CT in restaging after treatment for locally advanced non-small cell lung cancer

机译:EUS指导的细针穿刺抽吸术和PET-CT一体化治疗局部晚期非小细胞肺癌再分期的比较

获取原文
获取原文并翻译 | 示例
           

摘要

Background: After induction treatment restaging of mediastinal disease in patients with stage III non-small cell lung cancer (NSCLC) may lead to selection of candidates for further surgical treatment. Nodal down-staging is the best predictive characteristic for proceeding with surgery.We report our experience in restaging with endoscopic ultrasound-guided fine needle aspirations (EUS-FNA) and with repeated integrated positron emission tomography and computed tomography (PET-CT). Methods: Twenty-eight patients with stage III NSCLC were staged with integrated PET-CT, cerebral magnetic resonance imaging (MRI) and pathologically proven nodal disease.Restaging was performed with PET-CT and EUS-FNA on the same nodes that showed initially metastatic disease provided these nodal sites determined the tumor stage. Cerebral MRI was not repeated.When restaging EUS-FNA revealed no malignant cells anymore, patients were operated. The postoperative pathologic results were compared with the preoperative restaging EUS-FNA results. Also, patterns of decreased fluoro-2-deoxyglucose (FDG) uptake were compared with the postoperative pathologic results. Results: Restaging EUS-FNA was well tolerated in all patients even in those with clinical signs of radiation esophagitis.Of the 28 patients 15 were down-staged based on cytologic findings with restaging EUS-FNA and in one patient the cytology was not conclusive. Of these 15 patients, down-staging was histologically confirmed after mediastinal exploration in 11 patients and 1 patient had persistent nodal disease at resection. In 3 patients no mediastinal tissue verification was performed. Two subjects were not fit for operation, and in the other patient intraoperative nodal staging was omitted. The negative predictive value for restaging EUS-FNA was 91.6%. The accuracy of EUS-FNA was 92.3%.Concordance between findings of restaging EUS-FNA and metabolic response of lymph node metastases occurred in 17 out of 27 patients.Conclusion: Restaging with EUS-FNA after induction chemo(-radiotherapy) is well tolerated and predicts the absence of nodal metastasis reliably. Although changes in mediastinal FDG-PET uptake show a high concordance with EUS-FNA, pathological confirmation is still superior and therefore necessary. EUS-FNA is the procedure of first choice for mediastinal restaging.
机译:背景:诱导治疗后,III期非小细胞肺癌(NSCLC)患者的纵隔疾病重新分期可能导致选择进一步手术治疗的候选药物。淋巴结分期降低是进行外科手术的最佳预测特征。我们报告了在内镜超声引导下细针穿刺术(EUS-FNA)以及重复的正电子发射断层扫描和计算机断层扫描(PET-CT)进行分期的经验。方法:对28例III期NSCLC患者进行PET-CT整合,脑磁共振成像(MRI)并经病理证实的淋巴结转移分期,对PET-CT和EUS-FNA进行分期,在初发转移的同一节点进行分期如果这些淋巴结部位决定了肿瘤的分期,则该疾病得以解决。不再进行脑部MRI检查。重新分期EUS-FNA显示不再有恶性细胞时,便进行了手术。将术后病理结果与术前再分期EUS-FNA结果进行比较。此外,将氟-2-脱氧葡萄糖(FDG)摄取减少的模式与术后病理结果进行了比较。结果:即使在有放射食管炎临床症状的所有患者中,重新分期的EUS-FNA耐受性也很好.28例患者中,有15例因重新分期的EUS-FNA的细胞学检查结果而被下调,其中1例患者的细胞学检查尚无定论。在这15例患者中,有11例在进行纵隔探查后在组织学上证实了分期的降低,其中1例在切除后出现持续性淋巴结病。 3例患者未进行纵隔组织验证。两名受试者不适合手术,另一名患者术中未进行淋巴结分期。重新进行EUS-FNA的阴性预测值为91.6%。 EUS-FNA的准确率为92.3%.27例患者中有17例复发EUS-FNA的发现与淋巴结转移的代谢反应之间存在一致性。结论:诱导化疗(放疗)耐受EUS-FNA的耐受性良好并可靠地预测不存在淋巴结转移。尽管纵隔FDG-PET摄取量的变化与EUS-FNA高度吻合,但病理证实仍是优越的,因此是必要的。 EUS-FNA是纵隔再分期的首选方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号